# Comparison of the Effects of Tacrolimus and Cyclospori Mycophenolic Acid

Therapeutic Drug Monitoring

23, 119-128

DOI: 10.1097/00007691-200104000-00005

Citation Report

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Sirolimus: a comprehensive review. Expert Opinion on Pharmacotherapy, 2001, 2, 1903-1917. | 0.9 | 122 |
| 2 | Adverse Gastrointestinal Effects of Mycophenolate Mofetil. Drug Safety, 2001, 24, 645-663. | 1.4 | 288 |
| 3 | Comparative Clinical Pharmacokinetics of Tacrolimus in Paediatric and Adult Patients. Clinical Pharmacokinetics, 2001, 40, 283-295. | 1.6 | 124 |
| 4 | Therapeutic drug monitoring for immunosuppressants. Clinica Chimica Acta, 2001, 313, 241-253. | 0.5 | 88 |
| 5 | Effect of Cyclosporine on Mycophenolic Acid Area Under the Concentrationâ€“Time Curve in Pediatric Kidney Transplant Recipients. Therapeutic Drug Monitoring, 2001, 23, 514-519. | 1.0 | 58 |
| 6 | Effect of Cyclosporine Withdrawal on Mycophenolic Acid Pharmacokinetics in Kidney Transplant Recipients With Deteriorating Renal Function: Preliminary Report. Therapeutic Drug Monitoring, 2001, 23, 717-721. | 1.0 | 70 |
| 7 | In Vivo Higher Glucuronidation of Mycophenolic Acid in Male Than in Female Recipients of a Cadaveric Kidney Allograft and Under Immunosuppressive Therapy With Mycophenolate Mofetil. Therapeutic Drug Monitoring, 2001, 23, 520-525. | 1.0 | 42 |
| 8 | Inhibitors of the IMPDH Enzyme as Potential Anti-Bovine Viral Diarrhoea Virus Agents. Antiviral Chemistry and Chemotherapy, 2002, 13, 345-352. | 0.3 | 25 |
| 9 | Mycophenolic Acid and Mycophenolic Acid Glucuronide Pharmacokinetics in Pediatric Liver Transplant Recipients: Effect of Cyclosporine and Tacrolimus Comedication. Therapeutic Drug Monitoring, 2002, 24, 598-606. | 1.0 | 51 |
| 10 | Monitoring of Mycophenolic Acid in Clinical Transplantation. Therapeutic Drug Monitoring, 2002, 24, 68-73. | 1.0 | 40 |
| 11 | International Federation of Clinical Chemistry/International Association of Therapeutic Drug Monitoring and Clinical Toxicology Working Group on Immunosuppressive Drug Monitoring. Therapeutic Drug Monitoring, 2002, 24, 59-67. | 1.0 | 82 |
| 12 | Therapeutic drug monitoring of immunosuppressive drugs in kidney transplantation. Current Opinion in Nephrology and Hypertension, 2002, 11, 657-663. | 1.0 | 51 |
| 13 | Efficacy of mycophenolate sodium as monotherapy and in combination with FTY720 in a DA-to-Lewis-rat heart-transplantation model. Transplantation, 2002, 74, 1372-1376. | 0.5 | 7 |
| 14 | Monitoring mycophenolic acid. Annals of Clinical Biochemistry, 2002, 39, 173-183. | 0.8 | 55 |
| 15 | The transplanted child: New immunosuppressive agents and the need for pharmacokinetic monitoring. Paediatrics and Child Health, 2002, 7, 525-532. | 0.3 | 7 |
| 16 | Drug Interactions with Tacrolimus. Drug Safety, 2002, 25, 707-712. | 1.4 | 112 |
| 17 | Therapeutic Monitoring of Mycophenolate Mofetil in Organ Transplant Recipients. Clinical Pharmacokinetics, 2002, 41, 319-327. | 1.6 | 33 |
| 18 | Mechanisms of Clinically Relevant Drug Interactions Associated with Tacrolimus. Clinical Pharmacokinetics, 2002, 41, 813-851. | 1.6 | 272 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Value of mycophenolic acid trough level monitoring after lung transplantation. Transplantation Proceedings, 2002, 34, 1881-1883. | 0.3 | 4 |
| 20 | How pharmacokinetic and pharmacodynamic drug monitoring can improve outcome in solid organ transplant recipients. Transplant Immunology, 2002, 9, 211-214. | 0.6 | 22 |
| 21 | Mycophenolic acid concentrations in long-term heart transplant patients: relationship with calcineurin antagonists and acute rejection. Clinical Transplantation, 2002, 16, 196-201. | 0.8 | 20 |
| 22 | Glucocorticoids interfere with mycophenolate mofetil bioavailability in kidney transplantation. Kidney International, 2002, 62, 1060-1067. | 2.6 | 214 |
| 23 | Mycophenolic acid pharmacokinetics in pediatric liver transplant recipients. Liver Transplantation, 2003, 9, 383-388. | 1.3 | 35 |
| 24 | Mycophenolic Acid Pharmacodynamics and Pharmacokinetics Provide a Basis for Rational Monitoring Strategies. American Journal of Transplantation, 2003, 3, 534-542. | 2.6 | 219 |
| 25 | Liquid chromatography/mass spectrometry for therapeutic drug monitoring of immunosuppressants. Analytica Chimica Acta, 2003, 492, 133-145. | 2.6 | 33 |
| 26 | Anemia in children after transplantation: etiology and the effect of immunosuppressive therapy on erythropoiesis. Pediatric Transplantation, 2003, 7, 253-264. | 0.5 | 47 |
| 27 | Population pharmacokinetic analysis of mycophenolic acid in renal transplant recipients following oral administration of mycophenolate mofetil. British Journal of Clinical Pharmacology, 2003, 56, 188-197. | 1.1 | 56 |
| 28 | Can xipamide or tacrolimus inhibit the glucuronidation of mycophenolic acid in rat liver slices?. Experimental and Toxicologic Pathology, 2003, 54, 375-379. | 2.1 | 7 |
| 29 | Commentary on reducing infectious risks: polyoma (BK) virus. Transplantation Reviews, 2003, 17, S49. | 1.2 | 0 |
| 30 | Mycophenolate mofetil in solid-organ transplantation. Expert Opinion on Pharmacotherapy, 2003, 4, 2325-2345. | 0.9 | 67 |
| 31 | The influence of calcineurin inhibitors on mycophenolic acid pharmacokinetics. Transplantation Proceedings, 2003, 35, 2369-2371. | 0.3 | 26 |
| 32 | The influence of cyclosporine on mycophenolic acid plasma concentrations: a review. Transplantation Reviews, 2003, 17, 158-163. | 1.2 | 7 |
| 33 | Pharmacokinetics of tacrolimus-based combination therapies. Nephrology Dialysis Transplantation, 2003, 18, 12i-15. | 0.4 | 98 |
| 34 | Long-Term Changes in Mycophenolic Acid Exposure in Combination with Tacrolimus and Corticosteroids Are Dose Dependent and Not Reflected by Trough Plasma Concentration: A Prospective Study in 100 De Novo Renal Allograft Recipients. Journal of Clinical Pharmacology, 2003, 43, 866-880. | 1.0 | 99 |
| 35 | Randomized trial of tacrolimus + mycophenolate mofetil or azathioprine versus cyclosporine + mycophenolate mofetil after cadaveric kidney transplantation: results at three years. Transplantation, 2003, 75, 2048-2053. | 0.5 | 128 |
| 36 | Automated Determination of Free Mycophenolic Acid and Its Glucuronide in Plasma From Renal Allograft Recipients. Therapeutic Drug Monitoring, 2003, 25, 407-414. | 1.0 | 36 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Oral ulcers in kidney transplant recipients treated with sirolimus and mycophenolate mofetil. Transplantation, 2003, 75, 788-791. | 0.5 | 118 |
| 38 | Cyclosporin A, but Not Tacrolimus, Inhibits the Biliary Excretion of Mycophenolic Acid Glucuronide Possibly Mediated by Multidrug Resistance-Associated Protein 2 in Rats. Journal of Pharmacology and Experimental Therapeutics, 2004, 309, 1029-1035. | 1.3 | 178 |
| 39 | Low-Dose Sirolimus in Combination with Mycophenolate Mofetil Improves Kidney Graft Function Late after Renal Transplantation and Suggests Pharmacokinetic Interaction of Both Immunosuppressive Drugs. Kidney and Blood Pressure Research, 2004, 27, 181-185. | 0.9 | 21 |
| 40 | Drug Therapy in the Heart Transplant Recipient. Circulation, 2004, 110, 3858-3865. | 1.6 | 200 |
| 41 | Review of the immunosuppressant enteric-coated mycophenolate sodium. Expert Opinion on Pharmacotherapy, 2004, 5, 1333-1345. | 0.9 | 84 |
| 42 | Lack of Correlation Between MMF Dose and MPA Level in Pediatric and Young Adult Cardiac Transplant Patients: Does the MPA Level Matter?1. American Journal of Transplantation, 2004, 4, 1495-1500. | 2.6 | 33 |
| 43 | Ferrous sulfate does not affect mycophenolic acid pharmacokinetics in kidney transplant patients. American Journal of Kidney Diseases, 2004, 43, 1098-1103. | 2.1 | 28 |
| 44 | Current and Future Immunosuppressive Strategies in Renal Transplantation. Pharmacotherapy, 2004, 24, 1159-1176. | 1.2 | 60 |
| 45 | Effect of Mycophenolate Mofetil on the Pharmacokinetics of Antiretroviral Drugs and on Intracellular Nucleoside Triphosphate Pools. Clinical Pharmacokinetics, 2004, 43, 823-832. | 1.6 | 29 |
| 46 | Novel approaches to the therapy of steroid-resistant acute graft-versus-host disease. Biology of Blood and Marrow Transplantation, 2004, 10, 655-668. | 2.0 | 71 |
| 47 | Pharmacology of calcineurin antagonists. Transplantation Proceedings, 2004, 36, S25-S32. | 0.3 | 126 |
| 48 | Sustained suppression of peripheral blood immune functions by treatment with mycophenolate mofetil correlates with reduced severity of cardiac allograft rejection. Journal of Heart and Lung Transplantation, 2004, 23, 334-351. | 0.3 | 14 |
| 49 | Characterization of a Phase 1 Metabolite of Mycophenolic Acid Produced by CYP3A4/5. Therapeutic Drug Monitoring, 2004, 26, 600-608. | 1.0 | 65 |
| 50 | Comparison of Liquid Chromatography-Tandem Mass Spectrometry with a Commercial Enzyme-Multiplied Immunoassay for the Determination of Plasma MPA in Renal Transplant Recipients and Consequences for Therapeutic Drug Monitoring. Therapeutic Drug Monitoring, 2004, 26, 609-619. | 1.0 | 82 |
| 51 | Using Established Immunosuppressant Therapy Effectively. Therapeutic Drug Monitoring, 2004, 26, 347-351. | 1.0 | 46 |
| 52 | The Effect of 2-Gram Versus 1-Gram Concentration Controlled Mycophenolate Mofetil on Renal Transplant Outcomes Using Sirolimus-Based Calcineurin Inhibitor Drug-Free Immunosuppression. Transplantation, 2005, 79, 926-934. | 0.5 | 44 |
| 53 | The Rationale for and Limitations of Therapeutic Drug Monitoring for Mycophenolate Mofetil in Transplantation. Transplantation, 2005, 80, S244-S253. | 0.5 | 91 |
| 54 | Quantitative Analysis of the Immunosuppressant CP-690,550 in Whole Blood by Column-Switching High-Performance Liquid Chromatography and Mass Spectrometry Detection. Therapeutic Drug Monitoring, 2005, 27, 608-616. | 1.0 | 13 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | A Randomized, Prospective, Pharmacoeconomic Trial of Tacrolimus versus Cyclosporine in Combination with Thymoglobulin in Renal Transplant Recipients. Transplantation, 2005, 80, 41-46. | 0.5 | 60 |
| 56 | Mycophenolate Mofetil Substitution for Cyclosporine A in Renal Transplant Recipients with Chronic Progressive Allograft Dysfunction: The ???Creeping Creatinine??? Study1. Transplantation, 2005, 79, 466-475. | 0.5 | 154 |
| 57 | Conversion from Cyclosporine to Sirolimus in Stable Renal Transplant Recipients. Transplantation, 2005, 80, 1578-1585. | 0.5 | 54 |
| 58 | Mycophenolate Mofetil in Pediatric Renal Transplantation. Transplantation, 2005, 80, S201-S210. | 0.5 | 33 |
| 59 | Mycophenolic Acid Interaction With Cyclosporine and Tacrolimus In Vitro and In Vivo. Therapeutic Drug Monitoring, 2005, 27, 123-131. | 1.0 | 18 |
| 60 | Predicting the Usefulness of Therapeutic Drug Monitoring of Mycophenolic Acid. Therapeutic Drug Monitoring, 2005, 27, 163-167. | 1.0 | 32 |
| 61 | Pharmacokinetics and Bioavailability of Mycophenolic Acid After Intravenous Administration and Oral Administration of Mycophenolate Mofetil to Heart Transplant Recipients. Therapeutic Drug Monitoring, 2005, 27, 315-321. | 1.0 | 34 |
| 62 | Influence of Cyclosporine on the Serum Concentration and Biliary Excretion of Mycophenolic Acid and 7-O-Mycophenolic Acid Glucuronide. Therapeutic Drug Monitoring, 2005, 27, 132-138. | 1.0 | 20 |
| 63 | The Impact of Mycophenolate Mofetil on Long-Term Outcomes in Kidney Transplantation. Transplantation, 2005, 80, S211-S220. | 0.5 | 31 |
| 64 | Secondary effects of immunosuppressive drugs after simultaneous pancreasâ€“kidney transplantation. Nephrology Dialysis Transplantation, 2005, 20, ii33-ii39. | 0.4 | 18 |
| 65 | Drug interaction between mycophenolate mofetil and rifampin: Possible induction of uridine diphosphate-glucuronosyltransferase. Clinical Pharmacology and Therapeutics, 2005, 78, 81-88. | 2.3 | 71 |
| 66 | Higher exposure to mycophenolic acid with sirolimus than with cyclosporine cotreatment. Clinical Pharmacology and Therapeutics, 2005, 78, 34-42. | 2.3 | 31 |
| 67 | Genetic and nongenetic determinants of between-patient variability in the pharmacokinetics of mycophenolic acid. Clinical Pharmacology and Therapeutics, 2005, 78, 317-321. | 2.3 | 61 |
| 68 | Relationship of mycophenolic acid exposure to clinical outcome after hematopoietic cell transplantation. Clinical Pharmacology and Therapeutics, 2005, 78, 486-500. | 2.3 | 71 |
| 69 | Immunosuppressive drug monitoring - what to use in clinical practice today to improve renal graft outcome. Transplant International, 2005, 18, 140-150. | 0.8 | 60 |
| 70 | Mycophenolic acid pharmacokinetics and related outcomes early after renal transplant. British Journal of Clinical Pharmacology, 2005, 59, 271-280. | 1.1 | 97 |
| 71 | Characterizing the role of enterohepatic recycling in the interactions between mycophenolate mofetil and calcineurin inhibitors in renal transplant patients by pharmacokinetic modelling. British Journal of Clinical Pharmacology, 2005, 60, 249-256. | 1.1 | 82 |
| 72 | Cyclosporine Interacts with Mycophenolic Acid by Inhibiting the Multidrug Resistance-Associated Protein 2. American Journal of Transplantation, 2005, 5, 987-994. | 2.6 | 278 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | Pharmacokinetic Principles of Immunosuppressive Drugs. American Journal of Transplantation, 2005, 5, 207-217. | 2.6 | 59 |
| 74 | Influence of Co-Medication with Sirolimus or Cyclosporine on Mycophenolic Acid Pharmacokinetics in Kidney Transplantation. American Journal of Transplantation, 2005, 5, 2937-2944. | 2.6 | 72 |
| 75 | Addition of MMF to Dual Immunosuppression Does Not Increase the Risk of Malignant Short-Term Death After Liver Transplantation. American Journal of Transplantation, 2005, 5, 2961-2967. | 2.6 | 22 |
| 76 | Population pharmacokinetics of mycophenolic acid during the first week after renal transplantation. European Journal of Clinical Pharmacology, 2005, 61, 507-516. | 0.8 | 62 |
| 77 | A pilot study using mycophenolate mofetil in relapsing or resistant ANCA small vessel vasculitis. Nephrology Dialysis Transplantation, 2005, 20, 2725-2732. | 0.4 | 103 |
| 78 | Clinical Pharmacokinetic and Pharmacodynamic Monitoring for Mycophenolate Mofetil. Journal of Pharmacy Practice, 2005, 18, 422-431. | 0.5 | 2 |
| 79 | Immunosuppressant Drug Monitoring: Is the Laboratory Meeting Clinical Expectations?. Annals of Pharmacotherapy, 2005, 39, 119-127. | 0.9 | 25 |
| 80 | Short-term treatment with mycophenolic acid and tacrolimus is tolerogenic for INS-1 cell clone transplantation and the deleterious effects of the drugs are limited: in vivo and in vitro studies. Journal of Endocrinology, 2005, 186, 213-220. | 1.2 | 0 |
| 81 | A Phase I/II Study of Mycophenolate Mofetil in Combination with Cyclosporine for Prophylaxis of Acute Graft-versus-Host Disease after Myeloablative Conditioning and Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2005, 11, 495-505. | 2.0 | 115 |
| 82 | Glucuronidation in therapeutic drug monitoring. Clinica Chimica Acta, 2005, 358, 2-23. | 0.5 | 47 |
| 83 | Switching Immunosuppression From Cyclosporine to Tacrolimus Improves Long-Term Kidney Function: A 6-Year Study. Transplantation Proceedings, 2005, 37, 1898-1899. | 0.3 | 8 |
| 84 | Impact of Mycophenolate Mofetil Loading on Drug Exposure in the Early Posttransplant Period. Transplantation Proceedings, 2005, 37, 2320-2323. | 0.3 | 8 |
| 85 | Differential Effects of Cyclosporine and Tacrolimus on Mycophenolate Pharmacokinetics in Patients With Impaired Kidney Function. Transplantation Proceedings, 2005, 37, 1748-1750. | 0.3 | 19 |
| 86 | Mycophenolate mofetil in organ transplantation: focus on metabolism, safety and tolerability. Expert Opinion on Drug Metabolism and Toxicology, 2005, 1, 505-526. | 1.5 | 77 |
| 87 | Population Pharmacokinetics of Mycophenolic Acid in Renal Transplant Recipients. Clinical Pharmacokinetics, 2005, 44, 1083-1096. | 1.6 | 85 |
| 88 | Enteric-Coated Mycophenolate Sodium. Drugs, 2005, 65, 1037-1050. | 4.9 | 78 |
| 89 | Perioperative Management of Immunosuppression. Surgical Clinics of North America, 2006, 86, 1167-1183. | 0.5 | 14 |
| 90 | Individualisation of mycophenolate mofetil dose in renal transplant recipients. Expert Opinion on Pharmacotherapy, 2006, 7, 361-376. | 0.9 | 19 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin Aâ€"Containing and cyclosporin Aâ€"Free immunosuppressive regimens. Clinical Therapeutics, 2006, 28, 893-905. | 1.1 | 18 |
| 92 | Clinical Pharmacokinetics of Mycophenolate Mofetil in Japanese Renal Transplant Recipients: a Retrospective Cohort Study in a Single Center. Biological and Pharmaceutical Bulletin, 2006, 29, 2099-2105. | 0.6 | 11 |
| 93 | Effects of Calcineurin Inhibitors on Pharmacokinetics of Mycophenolic Acid and Its Glucuronide Metabolite during the Maintenance Period Following Renal Transplantation. Biological and Pharmaceutical Bulletin, 2006, 29, 275-280. | 0.6 | 47 |
| 94 | Characterization of Intestinal Absorption and Enterohepatic Circulation of Mycophenolic Acid and Its 7-O-Glucuronide in Rats. Drug Metabolism and Pharmacokinetics, 2006, 21, 406-413. | 1.1 | 15 |
| 95 | A Limited Sampling Model for Estimation of Total and Unbound Mycophenolic Acid (MPA) Area Under the Curve (AUC) in Hematopoietic Cell Transplantation (HCT). Therapeutic Drug Monitoring, 2006, 28, 394-401. | 1.0 | 28 |
| 96 | Tacrolimus as Intervention in the Treatment of Hyperlipidemia after Liver Transplant. Transplantation, 2006, 82, 494-500. | 0.5 | 41 |
| 97 | Therapeutic Drug Monitoring of Mycophenolate Mofetil in Transplantation. Therapeutic Drug Monitoring, 2006, 28, 145-154. | 1.0 | 305 |
| 98 | Multidrug Resistance Protein 2 Genetic Polymorphisms Influence Mycophenolic Acid Exposure in Renal Allograft Recipients. Transplantation, 2006, 82, 1074-1084. | 0.5 | 187 |
| 99 | Mycophenolic acid clinical pharmacokinetics influenced by a cyclosporine C2 based immunosuppressive regimen in renal allograft recipients. Transplant International, 2006, 19, 44-53. | 0.8 | 4 |
| 100 | Steroid withdrawal in living donor renal transplant recipients using tacrolimus and cyclosporine: a randomized prospective study*. Transplant International, 2006, 19, 478-484. | 0.8 | 13 |
| 101 | Evaluation of a surgical procedure to measure drug biliary excretion of rats in regulatory safety studies. Fundamental and Clinical Pharmacology, 2006, 20, 587-593. | 1.0 | 5 |
| 102 | Comparison of mycophenolic acid pharmacokinetic parameters in kidney transplant patients within the first 3 months post-transplant. Journal of Clinical Pharmacy and Therapeutics, 2006, 31, 27-34. | 0.7 | 44 |
| 103 | Rifampin induces alterations in mycophenolic acid glucuronidation and elimination: Implications for drug exposure in renal allograft recipients. Clinical Pharmacology and Therapeutics, 2006, 80, 509-521. | 2.3 | 73 |
| 104 | Total and free mycophenolic acid and its 7-O-glucuronide metabolite in Chinese adult renal transplant patients: pharmacokinetics and application of limited sampling strategies. European Journal of Clinical Pharmacology, 2006, 63, 27-37. | 0.8 | 35 |
| 105 | Current and Evolving Immunosuppressive Regimens in Kidney Transplantation. American Journal of Kidney Diseases, 2006, 47, S3-S21. | 2.1 | 46 |
| 106 | Portal vein thrombosis: Evolving techniques to attack this old nemesis portal vein thrombosis in patients undergoing orthotopic liver transplantation: intraoperative endovascular radiological procedures. Liver Transplantation, 2006, 12, 1166-1170. | 1.3 | 1 |
| 107 | Untreated Rejection in 6-Month Protocol Biopsies Is Not Associated with Fibrosis in Serial Biopsies or with Loss of Graft Function. Journal of the American Society of Nephrology: JASN, 2006, 17, 2622-2632. | 3.0 | 68 |
| 108 | ROLE OF MRP2 IN THE HEPATIC DISPOSITION OF MYCOPHENOLIC ACID AND ITS GLUCURONIDE METABOLITES: EFFECT OF CYCLOSPORINE. Drug Metabolism and Disposition, 2006, 34, 261-266. | 1.7 | 100 |

| # | Article | IF | Citations |
|---|---|---|---|
| 109 | Influence of Nonsynonymous Polymorphisms of UGT1A8 and UGT2B7 Metabolizing Enzymes on the Formation of Phenolic and Acyl Glucuronides of Mycophenolic Acid. Drug Metabolism and Disposition, 2006, 34, 1539-1545. | 1.7 | 91 |
| 110 | Mycophenolate mofetil: long-term outcomes in solid organ transplantation. Expert Review of Clinical Immunology, 2006, 2, 495-518. | 1.3 | 5 |
| 111 | Therapeutic Drug Monitoring of Mycophenolic Acid. Clinical Journal of the American Society of Nephrology: CJASN, 2007, 2, 1062-1072. | 2.2 | 74 |
| 112 | C-440T/T-331C polymorphisms in theUGT1A9gene affect the pharmacokinetics of mycophenolic acid in kidney transplantation. Pharmacogenomics, 2007, 8, 1127-1141. | 0.6 | 86 |
| 113 | Therapeutic Monitoring of Mycophenolate Mofetil. Clinical Journal of the American Society of Nephrology: CJASN, 2007, 2, 184-191. | 2.2 | 99 |
| 114 | Therapeutic drug monitoring of mycophenolic acid: does it improve patient outcome?. Expert Opinion on Drug Metabolism and Toxicology, 2007, 3, 251-261. | 1.5 | 32 |
| 115 | Conversion From Mycophenolate Mofetil to Enteric-Coated Mycophenolate Sodium in Maintenance Renal Transplant Recipients Receiving Tacrolimus: Clinical, Pharmacokinetic, and Pharmacodynamic Outcomes. Transplantation, 2007, 83, 417-424. | 0.5 | 71 |
| 116 | Validation of Immunological Biomarkers for the Pharmacodynamic Monitoring of Immunosuppressive Drugs in Humans. Therapeutic Drug Monitoring, 2007, 29, 77-86. | 1.0 | 60 |
| 117 | Concentrations of Mycophenolic Acid and Glucuronide Metabolites Under Concomitant Therapy With Cyclosporine or Tacrolimus. Therapeutic Drug Monitoring, 2007, 29, 87-95. | 1.0 | 20 |
| 118 | Oral Ulcers Produced by Mycophenolate Mofetil in Two Liver Transplant Patients. Transplantation Proceedings, 2007, 39, 612-614. | 0.3 | 28 |
| 119 | Anemia in the Period Immediately Following Renal Transplantation. Transplantation Proceedings, 2007, 39, 1446-1450. | 0.3 | 15 |
| 120 | Clinical Pharmacokinetics and Pharmacodynamics of Mycophenolate in Solid Organ Transplant Recipients. Clinical Pharmacokinetics, 2007, 46, 13-58. | 1.6 | 481 |
| 121 | Validation of limited sampling strategy for the estimation of mycophenolic acid exposure in Chinese adult liver transplant recipients. Liver Transplantation, 2007, 13, 1684-1693. | 1.3 | 18 |
| 122 | Simultaneous determination of cortisol, dexamethasone, methylprednisolone, prednisone, prednisolone, mycophenolic acid and mycophenolic acid glucuronide in human plasma utilizing liquid chromatographyâ€“tandem mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2007, 859, 42-51. | 1.2 | 76 |
| 123 | Calcineurin inhibitor-free immunosuppression in kidney transplantation. Transplant International, 2007, 20, 813-827. | 0.8 | 45 |
| 124 | Effects of gastric emptying on oral mycophenolic acid pharmacokinetics in stable renal allograft recipients. British Journal of Clinical Pharmacology, 2007, 63, 541-547. | 1.1 | 22 |
| 125 | Time-dependent clearance of mycophenolic acid in renal transplant recipients. British Journal of Clinical Pharmacology, 2007, 63, 741-752. | 1.1 | 63 |
| 126 | Results of an International, Randomized Trial Comparing Glucose Metabolism Disorders and Outcome with Cyclosporine Versus Tacrolimus. American Journal of Transplantation, 2007, 7, 1506-1514. | 2.6 | 530 |

| # | Article | IF | Citations |
|---|---|---|---|
| 127 | Individualized Mycophenolate Mofetil Dosing Based on Drug Exposure Significantly Improves Patient Outcomes After Renal Transplantation. American Journal of Transplantation, 2007, 7, 2496-2503. | 2.6 | 368 |
| 128 | Early conversion from cyclosporine to tacrolimus increases renal graft function in chronic allograft nephropathy at BANFF stages I and II. Transplant International, 2008, 21, 1153-1162. | 0.8 | 10 |
| 129 | Early, abrupt conversion of de novo renal transplant patients from cyclosporine to everolimus: results of a pilot study. Clinical Transplantation, 2008, 22, 366-371. | 0.8 | 38 |
| 130 | No pharmacokinetic interactions between mycophenolic acid and tacrolimus in renal transplant recipients. Journal of Clinical Pharmacy and Therapeutics, 2008, 33, 193-201. | 0.7 | 31 |
| 131 | Handbook of Drug Monitoring Methods. , 2008, , . | | 13 |
| 132 | A strong antioxidant isolated from grapefruit juice retentate. LWT - Food Science and Technology, 2008, 41, 420-424. | 2.5 | 3 |
| 133 | Pharmacodynamic monitoring of the conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in stable kidney-allograft recipients. International Immunopharmacology, 2008, 8, 769-773. | 1.7 | 17 |
| 134 | The impact of P-glycoprotein and Mrp2 on mycophenolic acid levels in mice. Transplant Immunology, 2008, 19, 192-196. | 0.6 | 38 |
| 135 | Models for the prediction of mycophenolic acid area under the curve using a limited-sampling strategy and an enzyme multiplied immunoassay technique in chinese patients undergoing liver transplantation. Clinical Therapeutics, 2008, 30, 2387-2401. | 1.1 | 15 |
| 136 | Influence of uridine diphosphate (UDP)-glucuronosyltransferases and ABCC2 genetic polymorphisms on the pharmacokinetics of mycophenolic acid and its metabolites in Chinese renal transplant recipients. Xenobiotica, 2008, 38, 1422-1436. | 0.5 | 49 |
| 137 | Pharmacokinetics of Mycophenolic Acid and its Phenolic-Glucuronide and Acyl Glucuronide Metabolites in Stable Thoracic Transplant Recipients. Therapeutic Drug Monitoring, 2008, 30, 282-291. | 1.0 | 26 |
| 138 | Comparison of Pharmacokinetics of Mycophenolic Acid and Its Glucuronide Between Patients With Lupus Nephritis and With Kidney Transplantation. Therapeutic Drug Monitoring, 2008, 30, 656-661. | 1.0 | 25 |
| 139 | Impact of Changing From Cyclosporine to Tacrolimus on Pharmacokinetics of Mycophenolic acid in Renal Transplant Recipients With Diabetes. Therapeutic Drug Monitoring, 2008, 30, 591-596. | 1.0 | 13 |
| 140 | Long-Term Pharmacokinetics of Mycophenolic Acid in Pediatric Renal Transplant Recipients Over 3 Years Posttransplant. Therapeutic Drug Monitoring, 2008, 30, 570-575. | 1.0 | 33 |
| 141 | Does the Evidence Support the Use of Mycophenolate Mofetil Therapeutic Drug Monitoring in Clinical Practice? A Systematic Review. Transplantation, 2008, 85, 1675-1685. | 0.5 | 119 |
| 142 | Decision Factors on Mycophenolic Acid Dose after Renal Transplantation. The Journal of the Korean Society for Transplantation, 2009, 23, 135-140. | 0.2 | 0 |
| 143 | A Review of Enteric-coated Mycophenolate Sodium for Renal Transplant Immunosuppression. Clinical Medicine Therapeutics, 2009, 1, CMT.S2218. | 0.1 | 2 |
| 144 | Mechanismâ€Based Enterohepatic Circulation Model of Mycophenolic Acid and Its Glucuronide Metabolite: Assessment of Impact of Cyclosporine Dose in Asian Renal Transplant Patients. Journal of Clinical Pharmacology, 2009, 49, 684-699. | 1.0 | 27 |

| # | Article | IF | Citations |
|---|---|---|---|
| 145 | Impact of Calcineurin Inhibitors on Urinary Excretion of Mycophenolic Acid and Its Glucuronide in Kidney Transplant Recipients. Journal of Clinical Pharmacology, 2009, 49, 710-718. | 1.0 | 13 |
| 146 | Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs. Expert Opinion on Drug Metabolism and Toxicology, 2009, 5, 703-729. | 1.5 | 194 |
| 147 | Mycophenolate mofetil in patients with systemic lupus erythematosus: a prospective pharmacokinetic study. Lupus, 2009, 18, 441-447. | 0.8 | 36 |
| 148 | The pharmacokinetics of mycophenolate mofetil in renal transplant recipients receiving standard-dose or low-dose cyclosporine, low-dose tacrolimus or low-dose sirolimus: the Symphony pharmacokinetic substudy. Nephrology Dialysis Transplantation, 2009, 24, 2269-2276. | 0.4 | 81 |
| 149 | Immunosuppressive therapy in lung transplantation: state of the art. European Journal of Cardio-thoracic Surgery, 2009, 35, 1045-1055. | 0.6 | 32 |
| 150 | Pharmacokinetics, efficacy, and safety of mycophenolate mofetil in combination with standard-dose or reduced-dose tacrolimus in liver transplant recipients. Liver Transplantation, 2009, 15, 136-147. | 1.3 | 36 |
| 151 | Pharmacokinetic role of protein binding of mycophenolic acid and its glucuronide metabolite in renal transplant recipients. Journal of Pharmacokinetics and Pharmacodynamics, 2009, 36, 541-564. | 0.8 | 73 |
| 152 | Mycophenolate mofetil combined with tacrolimus and minidose methotrexate after unrelated donor bone marrow transplantation with reduced-intensity conditioning. International Journal of Hematology, 2009, 89, 538-545. | 0.7 | 8 |
| 153 | Increased Mycophenolic Acid Exposure in Stable Kidney Transplant Recipients on Tacrolimus as Compared With Those on Sirolimus: Implications for Pharmacokinetics. Clinical Pharmacology and Therapeutics, 2009, 86, 411-415. | 2.3 | 20 |
| 154 | Orogenital ulcers in a liver transplant recipient: discerning between mycophenolateâ€mofetilâ€induced complication and Behcetâ€™s disease. Clinical Transplantation, 2009, 23, 147-149. | 0.8 | 5 |
| 155 | Measurement of mycophenolic acid and its glucuronide using a novel rapid liquid chromatographyâ€“electrospray ionization tandem mass spectrometry assay. Clinical Biochemistry, 2009, 42, 83-90. | 0.8 | 33 |
| 156 | Graft-versus-Host Disease Prophylaxis with Tacrolimus and Mycophenolate Mofetil in HLA-Matched Nonmyeloablative Transplant Recipients Is Associated with Very Low Incidence of GVHD and Nonrelapse Mortality. Biology of Blood and Marrow Transplantation, 2009, 15, 919-929. | 2.0 | 40 |
| 157 | Mycophenolic Acid Exposure after Administration of Mycophenolate Mofetil in the Presence and Absence of Ciclosporin in Renal Transplant Recipients. Clinical Pharmacokinetics, 2009, 48, 329-341. | 1.6 | 40 |
| 158 | Pharmacokinetic Modelling of the Plasma Protein Binding of Mycophenolic Acid in Renal Transplant Recipients. Clinical Pharmacokinetics, 2009, 48, 463-476. | 1.6 | 35 |
| 159 | Pharmacokinetic Optimization of Immunosuppressive Therapy in Thoracic Transplantation: Part I. Clinical Pharmacokinetics, 2009, 48, 419-462. | 1.6 | 55 |
| 160 | Pharmacokinetic Optimization of Immunosuppressive Therapy in Thoracic Transplantation: Part II. Clinical Pharmacokinetics, 2009, 48, 489-516. | 1.6 | 38 |
| 161 | Limited Sampling Models and Bayesian Estimation for Mycophenolic Acid Area under the Curve Prediction in Stable Renal Transplant Patients Co-Medicated with Ciclosporin or Sirolimus. Clinical Pharmacokinetics, 2009, 48, 745-758. | 1.6 | 52 |
| 162 | Mycophenolate pharmacokinetics and pharmacodynamics in belatacept treated renal allograft recipients â€“ a pilot study. Journal of Translational Medicine, 2009, 7, 64. | 1.8 | 10 |

| # | Article | IF | Citations |
|---|---|---|---|
| 163 | Immunotherapy in Elderly Transplant Recipients. Drugs and Aging, 2009, 26, 715-737. | 1.3 | 68 |
| 164 | Drug interactions in transplant patients: what everyone should know. Current Opinion in Nephrology and Hypertension, 2009, 18, 404-411. | 1.0 | 55 |
| 165 | New Insights Into the Pharmacokinetics and Pharmacodynamics of the Calcineurin Inhibitors and Mycophenolic Acid: Possible Consequences for Therapeutic Drug Monitoring in Solid Organ Transplantation. Therapeutic Drug Monitoring, 2009, 31, 416-435. | 1.0 | 146 |
| 166 | Mycophenolic Acid 12-Hour Area Under the Curve in De Novo Liver Transplant Patients Given Mycophenolate Mofetil at Fixed Versus Concentration-Controlled Doses. Therapeutic Drug Monitoring, 2009, 31, 451-456. | 1.0 | 7 |
| 167 | Performance of the New Mycophenolate Assay Based on IMPDH Enzymatic Activity for Pharmacokinetic Investigations and Setup of Bayesian Estimators in Different Populations of Allograft Recipients. Therapeutic Drug Monitoring, 2009, 31, 443-450. | 1.0 | 11 |
| 168 | Population Pharmacokinetic Analysis of Mycophenolic Acid Coadministered With Either Tasocitinib (CP-690,550) or Tacrolimus in Adult Renal Allograft Recipients. Therapeutic Drug Monitoring, 2010, 32, 778-781. | 1.0 | 17 |
| 169 | Developmental Pharmacogenetics of Immunosuppressants in Pediatric Organ Transplantation. Therapeutic Drug Monitoring, 2010, 32, 688-699. | 1.0 | 32 |
| 170 | Everolimus With Reduced Calcineurin Inhibitor in Thoracic Transplant Recipients With Renal Dysfunction: A Multicenter, Randomized Trial. Transplantation, 2010, 89, 864-872. | 0.5 | 126 |
| 171 | Two-Year Outcomes in Thoracic Transplant Recipients After Conversion to Everolimus With Reduced Calcineurin Inhibitor Within a Multicenter, Open-Label, Randomized Trial. Transplantation, 2010, 90, 1581-1589. | 0.5 | 64 |
| 172 | Inosine monophosphate dehydrogenase variability in renal transplant patients on longâ€term mycophenolate mofetil therapy. British Journal of Clinical Pharmacology, 2010, 69, 38-50. | 1.1 | 39 |
| 173 | Pharmacokinetic and pharmacodynamic analysis of entericâ€coated mycophenolate sodium: limited sampling strategies and clinical outcome in renal transplant patients. British Journal of Clinical Pharmacology, 2010, 69, 346-357. | 1.1 | 57 |
| 174 | Population pharmacokinetics and Bayesian estimator of mycophenolic acid in children with idiopathic nephrotic syndrome. British Journal of Clinical Pharmacology, 2010, 69, 358-366. | 1.1 | 34 |
| 175 | Risk of diarrhoea in a longâ€term cohort of renal transplant patients given mycophenolate mofetil: the significant role of the UGT1A8*2 variant allele. British Journal of Clinical Pharmacology, 2010, 69, 675-683. | 1.1 | 40 |
| 176 | Population pharmacokinetics of mycophenolic acid in children and young people undergoing blood or marrow and solid organ transplantation. British Journal of Clinical Pharmacology, 2010, 70, 567-579. | 1.1 | 25 |
| 177 | Does Tacrolimus, in Comparison With Sirolimus, Increase Mycophenolic Acid Exposure in Kidney Transplant Recipients?. Clinical Pharmacology and Therapeutics, 2010, 87, 650-1. | 2.3 | 1 |
| 178 | A clinical assessment of mycophenolate drug monitoring after liver transplantation. Clinical Transplantation, 2010, 24, E35-42. | 0.8 | 19 |
| 179 | Limited Sampling Strategies for Predicting Area Under the Concentration-Time Curve of Mycophenolic Acid in Islet Transplant Recipients. Annals of Pharmacotherapy, 2010, 44, 19-27. | 0.9 | 15 |
| 180 | Population Pharmacokinetics and Pharmacogenetics of Mycophenolic Acid Following Administration of Mycophenolate Mofetil in De Novo Pediatric Renalâ€Transplant Patients. Journal of Clinical Pharmacology, 2010, 50, 1280-1291. | 1.0 | 61 |

| # | Article | IF | Citations |
|---|---|---|---|
| 181 | MTX or mycophenolate mofetil with CsA as GVHD prophylaxis after reduced-intensity conditioning PBSCT from HLA-identical siblings. Bone Marrow Transplantation, 2010, 45, 1449-1456. | 1.3 | 43 |
| 182 | Can mycophenolic acid dose requirement during the first transplant help predict dosing for the second transplant?. Nephrology Dialysis Transplantation, 2010, 25, 3449-3452. | 0.4 | 2 |
| 183 | Mycophenolate Pharmacokinetics and Association with Response to Acute Graft-versus-Host Disease Treatment from the Blood and Marrow Transplant Clinical Trials Network. Biology of Blood and Marrow Transplantation, 2010, 16, 421-429. | 2.0 | 32 |
| 184 | Population pharmacokinetics of mycophenolic acid in pediatric renal transplant patients using parametric and nonparametric approaches. Pharmacological Research, 2011, 63, 216-224. | 3.1 | 34 |
| 185 | Renal Graft Function and Low-Dose Cyclosporine Affect Mycophenolic Acid Pharmacokinetics in Kidney Transplantation. Transplantation, 2011, 92, 550-556. | 0.5 | 7 |
| 186 | Mycophenolate monitoring in liver, thoracic, pancreas, and small bowel transplantation: a consensus report. Transplantation Reviews, 2011, 25, 65-77. | 1.2 | 23 |
| 187 | Optimization of the dosing regimen of mycophenolate mofetil in pediatric liver transplant recipients. Liver Transplantation, 2011, 17, 1152-1158. | 1.3 | 18 |
| 188 | Influence of MRP2 on MPA pharmacokinetics in renal transplant recipients-results of the Pharmacogenomic Substudy within the Symphony Study. Nephrology Dialysis Transplantation, 2011, 26, 3784-3793. | 0.4 | 37 |
| 189 | Mycophenolic Acid Pharmacokinetics During Maintenance Immunosuppression in African American and Caucasian Renal Transplant Recipients. Journal of Clinical Pharmacology, 2011, 51, 1213-1222. | 1.0 | 24 |
| 190 | Kidney and Pancreas Transplantation. , 2011, , . | | 4 |
| 191 | Adverse Drug Reactions and Drug-drug Interactions. , 2011, , 1569-1589. | | 2 |
| 192 | Comparison of MMF efficacy and safety in paediatric vs. adult renal transplantation: subgroup analysis of the randomised, multicentre FDCC trial. Nephrology Dialysis Transplantation, 2011, 26, 1073-1079. | 0.4 | 20 |
| 193 | Immunosuppressive Drug Monitoring. , 2012, , 323-348. | | 2 |
| 194 | Therapeutic Monitoring of Immunotherapies in Autoimmune Diseases. Current Pharmaceutical Design, 2012, 18, 4550-4555. | 0.9 | 5 |
| 195 | Factors Influencing Viral Clearing and Renal Function During Polyomavirus BKâ€“Associated Nephropathy After Renal Transplantation. Transplantation, 2012, 94, 396-402. | 0.5 | 42 |
| 196 | Pharmacokinetics of free mycophenolic acid and limited sampling strategy for the estimation of area under the curve in liver transplant patients. European Journal of Pharmaceutical Sciences, 2012, 47, 636-641. | 1.9 | 10 |
| 198 | The pharmacokinetic interaction between mycophenolic acid and cyclosporine revisited: a commentary on â€œMycophenolic acid glucuronide is transported by multidrug resistance-associated protein 2 and this transport is not inhibited by cyclosporine, tacrolimus or sirolimusâ€• Xenobiotica, 2013, 43, 836-838. | 0.5 | 10 |
| 199 | Genetic polymorphisms of UGT1A8, UGT1A9 and HNF-1Î± and gastrointestinal symptoms in renal transplant recipients taking mycophenolic acid. Transplant Immunology, 2013, 29, 155-161. | 0.6 | 5 |

| # | Article | IF | Citations |
|---|---|---|---|
| 200 | Predicting human exposure of active drug after oral prodrug administration, using a joined in vitro/in silicoâ€“in vivo extrapolation and physiologically-based pharmacokinetic modeling approach. Journal of Pharmacological and Toxicological Methods, 2013, 67, 203-213. | 0.3 | 18 |
| 201 | Population pharmacokinetics of unbound mycophenolic acid in adult allogeneic haematopoietic cell transplantation: effect of pharmacogenetic factors. British Journal of Clinical Pharmacology, 2013, 75, 463-475. | 1.1 | 26 |
| 202 | Population Pharmacokinetics and Dose Optimization of Mycophenolic Acid in HCT Recipients Receiving Oral Mycophenolate Mofetil. Journal of Clinical Pharmacology, 2013, 53, 393-402. | 1.0 | 40 |
| 203 | Prospective Randomized Trial of Maintenance Immunosuppression With Rapid Discontinuation of Prednisone in Adult Kidney Transplantation. American Journal of Transplantation, 2013, 13, 961-970. | 2.6 | 28 |
| 204 | Dose-normalization for exposure to mycophenolic acid and the early clinical outcome in patients taking tacrolimus after heart transplantation. Annals of Transplantation, 2013, 18, 43-52. | 0.5 | 7 |
| 205 | Clinical Pharmacology and Therapeutic Drug Monitoring of Immunosuppressive Agents. , 2013, , . | | 1 |
| 206 | Pharmacokinetic modeling of enterohepatic circulation of mycophenolic acid in renal transplant recipients. Kidney International, 2014, 85, 1434-1443. | 2.6 | 38 |
| 207 | Limited Sampling Model for Advanced Mycophenolic Acid Therapeutic Drug Monitoring After Liver Transplantation. Therapeutic Drug Monitoring, 2014, 36, 141-147. | 1.0 | 19 |
| 208 | 15-Year Follow-up of a Multicenter, Randomized, Calcineurin Inhibitor Withdrawal Study in Kidney Transplantation. Transplantation, 2014, 98, 47-53. | 0.5 | 41 |
| 209 | Effect of Cyclosporine on Steady-State Pharmacokinetics of MPA in Renal Transplant Recipients Is Not Affected by the MPA Formulation. Therapeutic Drug Monitoring, 2014, 36, 456-464. | 1.0 | 11 |
| 211 | Interplay of drug metabolizing enzymes with cellular transporters. Wiener Medizinische Wochenschrift, 2014, 164, 461-471. | 0.5 | 3 |
| 212 | Renal glucuronidation and multidrug resistance protein 2-/ multidrug resistance protein 4-mediated efflux of mycophenolic acid: interaction with cyclosporine and tacrolimus. Translational Research, 2014, 164, 46-56. | 2.2 | 29 |
| 213 | Clinical mycophenolic acid monitoring in liver transplant recipients. World Journal of Gastroenterology, 2014, 20, 10715. | 1.4 | 16 |
| 214 | Long-Term Follow-Up of a Phase III Clinical Trial Comparing Tacrolimus Extended-Release/MMF, Tacrolimus/MMF, and Cyclosporine/MMF in De Novo Kidney Transplant Recipients. Transplantation, 2014, 97, 636-641. | 0.5 | 72 |
| 215 | Concomitant Proton Pump Inhibitors With Mycophenolate Mofetil and the Risk of Rejection in Kidney Transplant Recipients. Transplantation, 2014, 97, 518-524. | 0.5 | 24 |
| 216 | Effect of uptake transporters OAT3 and OATP1B1 and efflux transporter MRP2 on the pharmacokinetics of eluxadoline. Journal of Clinical Pharmacology, 2015, 55, 534-542. | 1.0 | 38 |
| 217 | Influence of Sex and Race on Mycophenolic Acid Pharmacokinetics in Stable African American and Caucasian Renal Transplant Recipients. Clinical Pharmacokinetics, 2015, 54, 423-434. | 1.6 | 37 |
| 218 | Dosing algorithms for initiation of immunosuppressive drugs in solid organ transplant recipients. Expert Opinion on Drug Metabolism and Toxicology, 2015, 11, 921-936. | 1.5 | 28 |

| # | Article | IF | Citations |
|---|---|---|---|
| 219 | Mycophenolate revisited. Transplant International, 2015, 28, 508-515. | 0.8 | 73 |
| 220 | Rat Experimental Transplantation Surgery. , 2015, , . | | 5 |
| 221 | Risk factors of asymptomatic shedding of enteric pathogens in renal transplant recipients. Transplant Infectious Disease, 2016, 18, 480-482. | 0.7 | 1 |
| 222 | Reduced-dose methotrexate in combination with tacrolimus was associated with rapid engraftment and recovery from oral mucositis without affecting the incidence of GVHD. International Journal of Hematology, 2016, 104, 117-124. | 0.7 | 7 |
| 223 | Application of liquid chromatography combined with mass spectrometry or tandem mass spectrometry for therapeutic drug monitoring of immunosuppressants. , 2016, , 57-81. | | 5 |
| 224 | Pharmacokinetics of mycophenolic acid in children with clinically stable idiopathic nephrotic syndrome receiving cyclosporine. Clinical and Experimental Nephrology, 2017, 21, 152-158. | 0.7 | 6 |
| 225 | Steady-state pharmacokinetics of mycophenolic acid in renal transplant patients: exploratory analysis of the effects of cyclosporine, recipientsâ€™ and donorsâ€™ ABCC2 gene variants, and their interactions. European Journal of Clinical Pharmacology, 2017, 73, 1129-1140. | 0.8 | 11 |
| 226 | The combination of cyclosporine and mycophenolate mofetil is less effective than cyclosporine and methotrexate in the prevention of acute graftâ€versus host disease after stemâ€cell transplantation from unrelated donors. American Journal of Hematology, 2017, 92, 259-268. | 2.0 | 12 |
| 227 | The Impact of Total Gastrectomy on Pharmacokinetics in Kidney Transplant Immunosuppressive Drug Regimes. Transplantation, 2017, 101, 2213-2217. | 0.5 | 4 |
| 229 | Pharmacokinetics and dynamics of mycophenolate mofetil after singleâ€dose oral administration in juvenile dachshunds. Journal of Veterinary Pharmacology and Therapeutics, 2017, 40, e1-e10. | 0.6 | 9 |
| 230 | Immunosuppression for in vivo research: state-of-the-art protocols and experimental approaches. Cellular and Molecular Immunology, 2017, 14, 146-179. | 4.8 | 99 |
| 231 | High frequency of valganciclovir underdosing for cytomegalovirus prophylaxis after renal transplantation. CKJ: Clinical Kidney Journal, 2018, 11, 564-573. | 1.4 | 13 |
| 232 | Pharmacokinetics and Safety of Letermovir Coadministered With Cyclosporine A or Tacrolimus in Healthy Subjects. Clinical Pharmacology in Drug Development, 2018, 7, 9-21. | 0.8 | 70 |
| 233 | Prediction of Free from Total Mycophenolic Acid Concentrations in Stable Renal Transplant Patients: A Population-Based Approach. Clinical Pharmacokinetics, 2018, 57, 877-893. | 1.6 | 20 |
| 234 | Tacrolimus-Induced Remission in Drug Resistant Inflammatory Myopathy: A Case Series. Rheumatology (Sunnyvale, Calif ), 2018, 08, . | 0.3 | 2 |
| 235 | Tolerability of mycophenolate sodium in renal transplant recipients. International Journal of Clinical Pharmacy, 2018, 40, 1548-1558. | 1.0 | 4 |
| 236 | Pharmacokinetics Evaluation of Mycophenolic Acid and Its Glucuronide Metabolite in Chinese Renal Transplant Recipients Receiving Enteric-Coated Mycophenolate Sodium and Tacrolimus. Therapeutic Drug Monitoring, 2018, 40, 572-580. | 1.0 | 4 |
| 237 | Drug-Induced Hematological Cytopenia in Kidney Transplantation and the Challenges It Poses for Kidney Transplant Physicians. Journal of Transplantation, 2018, 2018, 1-22. | 0.3 | 25 |

| # | Article | IF | Citations |
|---|---|---|---|
| 238 | The Bile Sequestrant Cholestyramine Increases Survival in a Rabbit Model of Brodifacoum Poisoning. Toxicological Sciences, 2018, 165, 389-395. | 1.4 | 10 |
| 239 | Limited Sampling Strategy for the Estimation of Mycophenolic Acid and its Acyl Glucuronide Metabolite Area under the Concentration-Time Curve in Japanese Lung Transplant Recipients. Journal of Pharmacy and Pharmaceutical Sciences, 2019, 22, 407-417. | 0.9 | 6 |
| 240 | Influence of Calcineurin Inhibitor and Sex on Mycophenolic Acid Pharmacokinetics and Adverse Effects Postâ€"Renal Transplant. Journal of Clinical Pharmacology, 2019, 59, 1351-1365. | 1.0 | 9 |
| 241 | Azathioprine and Mycophenolates. , 2019, , 212-230. | | 1 |
| 242 | Optimizing Mycophenolic Acid Exposure in Kidney Transplant Recipients: Time for Target Concentration Intervention. Transplantation, 2019, 103, 2012-2030. | 0.5 | 43 |
| 243 | Systematic external evaluation of published population pharmacokinetic models of mycophenolate mofetil in adult kidney transplant recipients coâ€administered with tacrolimus. British Journal of Clinical Pharmacology, 2019, 85, 746-761. | 1.1 | 23 |
| 244 | Immunosuppressive drugs and the gastrointestinal tract in renal transplant patients. Transplantation Reviews, 2019, 33, 55-63. | 1.2 | 18 |
| 245 | ABCC2 c.-24 C>T single-nucleotide polymorphism was associated with the pharmacokinetic variability of deferasirox in Chinese subjects. European Journal of Clinical Pharmacology, 2020, 76, 51-59. | 0.8 | 11 |
| 246 | Initial mycophenolate dose in tacrolimus treated renal transplant recipients, a cohort study comparing leukopaenia, rejection and long-term graft function. Scientific Reports, 2020, 10, 19379. | 1.6 | 9 |
| 247 | Effect of the proton-pumpÂInhibitor pantoprazole on MycoPhenolic ACid exposure in kidney and liver transplant recipienTs (IMPACT study): a randomized trial. Nephrology Dialysis Transplantation, 2020, 35, 1060-1070. | 0.4 | 8 |
| 248 | Population pharmacokinetics of mycophenolic acid in paediatric patients. British Journal of Clinical Pharmacology, 2021, 87, 1730-1757. | 1.1 | 15 |
| 249 | Population pharmacokinetics of mycophenolic acid in pediatric patients with juvenile dermatomyositis and optimization of limited sampling strategy. Xenobiotica, 2021, 51, 167-176. | 0.5 | 4 |
| 250 | Voclosporin: a novel calcineurin inhibitor with no impact on mycophenolic acid levels in patients with SLE. Nephrology Dialysis Transplantation, 2022, 37, 917-922. | 0.4 | 19 |
| 251 | Targeted delivery of mycophenolic acid to the mesenteric lymph node using a triglyceride mimetic prodrug approach enhances gut-specific immunomodulation in mice. Journal of Controlled Release, 2021, 332, 636-651. | 4.8 | 16 |
| 252 | Limited Sampling Strategy for Estimation of Mycophenolic Acid Exposure in Adult Chinese Heart Transplant Recipients. Frontiers in Pharmacology, 2021, 12, 652333. | 1.6 | 6 |
| 253 | Personalized Therapy for Mycophenolate: Consensus Report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. Therapeutic Drug Monitoring, 2021, 43, 150-200. | 1.0 | 89 |
| 254 | Induction and maintenance immunosuppression in pediatric kidney transplantationâ€"Advances and controversies. Pediatric Transplantation, 2021, 25, e14077. | 0.5 | 10 |
| 255 | How cyclosporine reduces mycophenolic acid exposure by 40% while other calcineurin inhibitors do not. Kidney International, 2021, 100, 1185-1189. | 2.6 | 17 |

| # | Article | IF | Citations |
|---|---|---|---|
| 256 | Effects of Corticosteroid Treatment on Mycophenolic Acid Exposure in Renal Transplant Patientsâ€"Results From the SAILOR Study. Frontiers in Pharmacology, 2021, 12, 742444. | 1.6 | 2 |
| 257 | Baicalin ameliorates cigarette smoke-induced airway inflammation in rats by modulating HDAC2/NF-Î²B/PAI-1 signalling. Pulmonary Pharmacology and Therapeutics, 2021, 70, 102061. | 1.1 | 22 |
| 258 | Drug Interactions in Solid Organ Transplant Recipients. , 2014, , 411-425. | | 2 |
| 259 | Immunosuppressive Drugs. , 2008, , 165-199. | | 4 |
| 260 | Pharmacologic Treatment of Transplant Recipients Infected With SARS-CoV-2: Considerations Regarding Therapeutic Drug Monitoring and Drugâ€"Drug Interactions. Therapeutic Drug Monitoring, 2020, 42, 360-368. | 1.0 | 48 |
| 261 | Development of a Predictive Limited Sampling Strategy for Estimation of Mycophenolic Acid Area Under the Concentration Time Curve in Patients Receiving Concomitant Sirolimus or Cyclosporine. Therapeutic Drug Monitoring, 2008, 30, 445-455. | 1.0 | 14 |
| 262 | Inosine 5â€²-Monophosphate Dehydrogenase Activity for the Longitudinal Monitoring of Mycophenolic Acid Treatment in Kidney Allograft Recipients. Transplantation, 2021, 105, 916-927. | 0.5 | 7 |
| 263 | Late Conversion of Kidney Transplant Recipients from Ciclosporin to Tacrolimus Improves Graft Function: Results from a Randomized Controlled Trial. PLoS ONE, 2015, 10, e0135674. | 1.1 | 3 |
| 264 | A delicate balance between rejection and BK polyomavirus associated nephropathy; A retrospective cohort study in renal transplant recipients. PLoS ONE, 2017, 12, e0178801. | 1.1 | 13 |
| 265 | Proton pump inhibitors and adverse effects in kidney transplant recipients: A meta-analysis. World Journal of Transplantation, 2019, 9, 35-47. | 0.6 | 13 |
| 266 | Limited Sampling Strategy for Estimating Area under the Concentration Curve for Mycophenolic Acid in Renal Transplant Recipients with Co-administration of Tacrolimus.. Iryo Yakugaku (Japanese Journal) Tj ETQq0 0 0 rgBT /Overlock 10 Tf | 0.0 | 8 |
| 267 | Insulin Requirement After a Renal Transplant in Patients With Type 2 Diabetes: The Choice of Calcineurin Inhibitors. Experimental and Clinical Transplantation, 2013, 11, 234-238. | 0.2 | 3 |
| 268 | 4. Mycophenolate Mofetil. Japanese Journal of Clinical Pharmacology and Therapeutics, 2005, 36, 63-68. | 0.1 | 2 |
| 269 | TRANSPLANT MEDICINE. , 2009, , 1269-1294. | | 0 |
| 271 | Immunosuppressive Therapy in Kidney and Pancreas Transplantation. , 2011, , 49-86. | | 0 |
| 272 | Clinical Pharmacologic Principles and Immunosuppression. , 2011, , 87-109. | | 0 |
| 273 | Mycophenolic acid agents: is enteric coating the answer?. Transplant Research and Risk Management, 0, , 45. | 0.7 | 0 |
| 274 | Mycophenolic Acid Absorption Profiles in Patients with Kidney or Combined Pancreas-Kidney Transplantation. Open Journal of Nephrology, 2012, 02, 116-122. | 0.0 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 276 | Mycophenolates. , 2014, , 250-266. | | 0 |
| 277 | Immunosuppresive Drugs Commonly Used in Transplantation Models. , 2015, , 19-29. | | 0 |
| 278 | Comparative Study of Mycophenolate Mofetil and Methotrexate in Graft-Versus-Host Disease Prophylaxis in Adult Recipients of Related and Unrelated Allo-HSCT. Klinicheskaya Onkogematologiya/Clinical Oncohematology, 2019, 12, 43-50. | 0.1 | 0 |
| 279 | Induction and Maintenance Agents. Organ and Tissue Transplantation, 2019, , 1-11. | 0.0 | 0 |
| 280 | Induction and Maintenance Agents. Organ and Tissue Transplantation, 2020, , 193-203. | 0.0 | 0 |
| 281 | Therapeutic drug monitoring of immunosuppressants. , 2020, , 317-332. | | 0 |
| 282 | Severe Mycophenolate Intoxication in a Solid Organ Transplant Recipientâ€"No Intervention Actually Needed. Transplantation Direct, 2020, 6, e609. | 0.8 | 0 |
| 283 | Impact of UGT1A9 Polymorphism on Mycophenolic Acid Pharmacokinetic Parameters in Stable Renal Transplant Patients. Iranian Journal of Pharmaceutical Research, 2013, 12, 547-56. | 0.3 | 13 |
| 284 | Drug-Drug Interactions among Kidney Transplant Recipients in The Outpatient Setting. International Journal of Organ Transplantation Medicine, 2020, 11, 185-195. | 0.5 | 1 |
| 285 | Limited Sampling Strategies to Monitoring Mycophenolic Acid Exposure in a Heterogeneous Population of Heart Transplant Recipients: A Pilot Study. , 0, , . | | 0 |
| 288 | Study on the Protective Effect and Mechanism of the Rhizoma Drynariae-Epimedium Formula on Osteoarthritis in Rats. Contrast Media and Molecular Imaging, 2022, 2022, 1-8. | 0.4 | 4 |
| 289 | Effects of Coix Seed Extract, Bifidobacterium BPL1, and Their Combination on the Glycolipid Metabolism in Obese Mice. Frontiers in Nutrition, 0, 9, . | 1.6 | 6 |
| 290 | Population Pharmacokinetics of Enteric-Coated Mycophenolate Sodium in Children after Renal Transplantation and Initial Dosage Recommendation Based on Body Surface Area. Computational and Mathematical Methods in Medicine, 2022, 2022, 1-18. | 0.7 | 0 |
| 291 | AvaliaÃ§Ã£o da nefrotoxicidade pelo tacrolimus e micofenolato mofetil associados Ã isquemia e reperfusÃ£o renal: estudo experimental em ratos. Revista Do Colegio Brasileiro De Cirurgioes, 0, 49, . | 0.3 | 0 |
| 292 | Evaluation of nefrotoxicity by tacrolimus and micophenolate mofetil associated with kidney ischemia and reperfusion: experimental study in rats. Revista Do Colegio Brasileiro De Cirurgioes, 0, 49, . | 0.3 | 1 |
| 293 | Shengjiang San alleviated sepsis-induced lung injury through its bidirectional regulatory effect. Chinese Medicine, 2023, 18, . | 1.6 | 1 |